Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants
Authors:
Open Access
- 1 September 2015
- journal article
- review article
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. ume 10, 1431-1444
Abstract
Stroke prevention in elderly atrial fibrillation patients remains a challenge. There is a high risk of stroke and systemic thromboembolism but also a high risk of bleeding if anticoagulants are prescribed. The elderly have increased chronic kidney disease, coronary artery disease, polypharmacy, and overall frailty. For all these reasons, anticoagulant use is underutilized in the elderly. In this manuscript, the benefits of non-vitamin K antagonist oral anticoagulants compared with warfarin in the elderly patient population with multiple comorbid conditions are reviewed.Keywords
This publication has 90 references indexed in Scilit:
- Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in CombinationJournal of Cardiovascular Pharmacology, 2012
- Is Frailty a Prodromal Stage of Vascular Dementia? Results From the T hree‐ C ity S tudyJournal of the American Geriatrics Society, 2012
- Rivaroxaban in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trialEuropean Heart Journal, 2011
- Anticoagulant and Antiplatelet Usage Associates with Mortality among Hemodialysis PatientsJournal of the American Society of Nephrology, 2009
- Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic SurgeryClinical Pharmacokinetics, 2008
- Decreased Glomerular Filtration Rate Is a Risk Factor for Hemorrhagic But Not for Ischemic StrokeStroke, 2007
- Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial FibrillationAnnals of Internal Medicine, 2007
- Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by AspirinThe Journal of Clinical Pharmacology, 2006
- Frailty in Older Adults: Evidence for a PhenotypeThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2001